By Th. Büchner (auth.), W. Hinterberger, A. J. Barrett, K. Lechner, E. Deutsch (eds.)
Read Online or Download 11th Annual meeting of the EBMT: European Cooperative Group for Bone Marrow Transplantation PDF
Best european books
This publication bargains with festival coverage from the perspective of a enterprise govt. It permits a hectic reader to move immediately to the company perform with which he's involved and from there to a precis of the professionals' remedy of that perform. while, it presents the reader who needs so as to add an appreciation of anti-trust compliance to his specialist portfolio with a accomplished review of the topic, including a advisor to worthwhile resources of extra details.
- Recent Advances in Parallel Virtual Machine and Message Passing Interface: 11th European PVM/MPI Users’ Group Meeting Budapest, Hungary, September 19 - 22, 2004. Proceedings
- European Sustainable Carriage of Goods: The Role of Contract Law
- Ultrasonic Tissue Characterization: Proceedings of the Second European Communities Workshop 30 November – 2 December 1981, Nijmegen, The Netherlands
- European Union Civil Society Policy and Turkey: A Bridge Too Far?
Extra resources for 11th Annual meeting of the EBMT: European Cooperative Group for Bone Marrow Transplantation
24 adult patients while in remission of AL were consolidated by Cyclophosphamide 60 mg/kg X 2 and total body irradiation at 10 Grays followed by ABMT with marrow cleansed by ASTA Z 7557 according to the specifications described above. All patients engrafted leukocytes (median day for recovery to ]09/1 = day 30). Delayed kinetics of recovery of platelets were observed in some ANLL patients. In the group of standard prognosis (13 patients), 11 patients have remained in CR or disease free with a median follow up of 12 months (]2+ to 20+ months).
Patients with ANLL shou1d not be autograftcd beyond CRJ. 2) Although marrow purging may improve the resu1ts for patients with ALL in CR2, there is yet no definitive conc1usion. Thcrefore at present time both cleansed and non clcansed marrow may be used. 3) Give preference - to patients with standard risk leukemia in CRJ - to TBI - to optimal c1eansing with ASTA Z 7557 at appropriate dosage. -AUTDLDCOiJSBÜiT[ f1ARRDVI TRANSPLANTATION IN EUROPE PATIENTS UITH ACUTF LEUKENIA IN REMISSION. TEAf~ COORDINATOR NIJI'IBER OF PA TIENTS BESANCON HERVE 35 ST ANTOINE GOR IN 25 BLOOMSBURY GOLDSTONE 23 GLASGQ\,J BURNETT ll LEIPZIG HELBIG 1] ROMA ~1ELONI 8 UTRECHT VERDONCK 8 PARMA RIZZOLI 7 NANTES HARDUSSEAU 6 GENOVA CARELLA 5 BERNE BRUN DEL RE 3 PARMA + GENOVA RIZZOLI + CARELLA 2 ROYAL FREE HOSP.
Brk. lym. oth. grd. grd. grd. grd. D MC 9 5 1 0 1 9 4 110 22 13 10 51 14 (D=diagnosis, A=responding relapse, B=resistant relapse) Inrounology 34 Unknawn 20 (NHL ~nly)T-cell 16 B-cell 3 Null 8 True histiocytic Conditioning Chemotherapy: HD 28 NHL 62 1 NHL 19 HD Chemo & DXR: Purging had marrow purged 10/llO with T monoclonal l with 4 HC 2 with Asta 7 7 Results Haemopoietic recovery is shown in relation to dose in Table 1. Table 1. NHL & HD (llO) Mean Time Mean time Nucl. ,.. 0 X 10 /1, platelets 750 X 10 /1.